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Development of anti-retroviral regimens with enhanced efficacy against brain HIV-1 is essential if viral eradication is to be
achieved. To address this, a severe combined immune deficiency mouse model of HIV-1 encephalitis was used to assay the
effect of protease-containing and protease-sparing drug regimens on viral replication in brain macrophages. Here, HIV-1-
infected human monocyte-derived macrophages (MDM) are inoculated into basal ganglia, causing a multinucleated giant cell
encephalitis reminiscent of human disease. Drugs were administered at the time of MDM inoculation and continued until
sacrifice. Immunohistochemical tests evaluated ongoing viral replication, glial immunity, and neuronal survival. Treatment
with ddI/d4T decreased the numbers of infected cells by 75%, while ddI/d4T/amprenavir or ZDV/3TC/ABC diminished
infection by 98%. Triple drug regimens decreased astrogliosis by $25%. This small-animal model may be used to screen drug
regimens that affect ongoing HIV-1 replication within its brain sanctuary. © 2001 Academic Press
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HIV-1-associated dementia (HAD) is a devastating
complication of progressive viral infection and is usually
associated with profound immunosuppression (Janssen
et al., 1991). Despite the advent of potent anti-retroviral
medicines, 7% of infected individuals still succumb to
progressive cognitive decline (Dore et al., 1999). The
clinical syndrome usually occurs late in the course of
viral infection but progresses rapidly from subtle cogni-
tive changes and physical slowing, to florid memory loss,
behavioral abnormalities, incontinence, hallucinations,
seizures, and ultimately death (Kieburtz and Schiffer,
1989; Navia et al., 1986; Price et al., 1988; Wiley and
chim, 1994). The pathogenesis of HAD revolves around
ustained viral replication and immune activation of
rain mononuclear phagocytes (MP) (microglia, perivas-
ular macrophages, and parenchymal macrophages). In-
eed, the numbers of immune competent macrophages,
ot the absolute levels of virus per se, are the major
redictors for dementia (Glass et al., 1995). Virus-in-
ected and/or immune competent MP secrete high levels
f neurotoxins, including, but not limited to, cellular fac-
1 The first two authors contributed equally to this work.
2 To whom correspondence and reprint requests should be ad-
dressed at the Center for Neurovirology and Neurodegenerative Dis-
f
s
orders, 985215 Nebraska Medical Center, Omaha NE 68198-5215. Fax:
(402) 559-8922. E-mail: hegendel@unmc.edu.
21ors such as tumor necrosis factor a (TNFa), platelet
ctivating factor, arachidonic acid and its metabolites,
itric oxide, quinolinic acid, glutamate, and viral toxins
HIV-1 gp120, tat, nef, and rev) (Bukrinsky et al., 1995;
elbard et al., 1994; Genis et al., 1992; Griffin et al., 1994;
eyes et al., 1991; Lipton et al., 1993; Nottet et al., 1995;
yor et al., 1992; Wesselingh et al., 1993). While most
atients with HAD and advanced immunosuppression
ave high levels of virus in their brains (Wiley and Achim,
994), the converse is not always true (Dickson et al.,
991; Gendelman et al., 1994; Kure et al., 1990; Wiley and
chim, 1994). This suggests that both viral and cellular
actors amplify the production of one another and play
rominent roles in disease onset and progression.
Virus-infected MP are the major cellular target for
IV-1 in infected brain tissue. Productive viral replication
n MP is necessary, but not sufficient, to cause HAD.
onetheless, the abrogation of viral production in the
entral nervous system (CNS) could serve to eliminate
oth the brain viral reservoir and neurological impair-
ents associated with HAD. Anti-retroviral therapies that
arget the brain must affect HIV-1 replication in macro-
hages. This is not an easy task, as viral replication
ontained within MP has several means by which it can
scape targeted anti-retroviral therapies. These include
he known poor blood–brain barrier penetration by anti-
etroviral drugs, viral mutation, macrophage secretory
actors that serve to regulate viral production, and “back-
eeding” or back-mutation of HIV-1 from brain to blood.
0042-6822/01 $35.00
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22 LIMOGES ET AL.Further, since viral infection of the CNS is necessary to
affect the onset and progression of HAD, anti-retroviral
therapies may affect viral levels in brain but incompletely
retard MP inflammatory responses. Both are critical el-
ements in disease as they can effect neural demise.
To date, monitoring potent anti-retroviral efficacy dur-
ing HAD has been generally limited to changes in neu-
ropsychological testing, monitoring of CNS inflammation,
imaging of diseased brain, and measurements of viral
load in the plasma and cerebrospinal fluid (CSF). All of
these tests, together, cannot directly measure what can
occur within an infected brain. Therefore, the use of
animal models to monitor anti-retroviral efficacy is of
potential importance for the purposes of screening anti-
retroviral and adjuvant (anti-inflammatory and neuropro-
tective) regimens (McArthur and Kieburtz, 2000).
To these ends, we developed a severe combined im-
munodeficiency (SCID) mouse model of HIV-1 encepha-
litis (HIVE) (Persidsky et al., 1996). The most common
pathological correlate of HAD is HIVE (Wiley and Achim,
1994), a multinucleated giant cell encephalitis, which
includes the accumulation and activation of astrocytes
and MP (microglial nodules and multinucleated giant
cells) in subcortical white and deep gray matter. The
HIVE SCID model has a number of notable features for
studies of potential therapeutics: (1) it recapitulates
many pathophysiological features of human HAD; (2) it
parallels the neuroinflammatory and behavior profiles
demonstrated in human disease (Avgeropoulos et al.,
1998; Persidsky et al., 1997); and (3) it allows testing of
anti-retroviral agents for therapeutic efficacy in prevent-
ing viral spread in a blood–brain barrier-protected CNS
(Limoges et al., 2000). Here, we used the HIVE SCID
mouse model to compare protease-containing and pro-
tease-sparing regimens to affect HIV-1 replication in
brain. Animals were treated with drug prior to the intra-
cerebral inoculation of infected MDM and continuously
thereafter. Brain tissue was analyzed at serial time points
for viral replication and immunological activation. The
results provide insights into how potent anti-retroviral
therapies (PART) can be administered to achieve maxi-
mal ablation of ongoing HIV-1 replication in infected
brain tissue.
RESULTS
The impetus for this work is whether potent anti-
retroviral testing could be performed in a SCID mouse
model of HIVE and whether the results would be appli-
cable for treatment of human disease. Such queries
were addressed, in part, in a prior publication utilizing
single anti-retroviral therapy for HIVE treatments in this
SCID mouse model of disease (Limoges et al., 2000) and
n the accompanying editorial on the topic (McArthur and
ieburtz, 2000).
(
seuropathological features of HIVE in humans and
CID mice
The pathogenesis of HAD is rapidly being eluci-
ated. The prevailing theory of disease is that secre-
ory products from immune activated virus-infected
P drive a reversible metabolic encephalopathy that
eads, over time, to neuronal demise. This continues,
eading to cognitive dysfunction, if viral replication is
eft unchecked. HIVE is considered to be the best
orphological correlate of HAD (Wiley and Achim,
994). Virus-associated encephalitis is characterized
y HIV-1 infection of perivascular macrophages and
icroglia and by MP giant cell formation (Figs. 1A and
C). Perivascular macrophage infiltration, microglial
odules (Fig. 1E), and astrogliosis (Fig. 1G) are also
ommon features of disease pathology. Microglial ac-
ivation (detected as MHC class II expression) may
erve as the best predictor of HIVE severity (Persidsky
t al., 1999), while synaptic loss parallels clinical men-
al deterioration (Masliah et al., 1997). Interestingly,
ome areas of the brain (white matter and basal gan-
lia) are affected more than others and to a certain
xtent may explain HAD. In order to mimic pathogenic
eatures of disease, we have developed a murine
nimal model of HIVE (Persidsky et al., 1996). Virus-
nfected human monocyte-derived macrophages
MDM) are stereotactically inoculated in the basal
anglia of SCID mice. By 7 days after MDM inocula-
ion, salient features of HIVE are reproduced and in-
lude immune activation and infection of MP, giant cell
ormation (Figs. 1B and 1D), microglial activation (Fig.
F), astrogliosis (Fig. 1H), and neuronal dendritic dam-
ge and death. Examination of SCID mouse brain
issue by transmission electron microscopy showed a
erivascular location of human HIV-1-infected MDM
nd intact tight junctions between brain endothelial
ells (ensuring structural tightness of the blood–brain
arrier) (Fig. 2). End-feet processes of reactive astro-
ytes extended to the ablumenal membrane of endo-
helial cells and contained increased amounts of gly-
ogen.
To evaluate the efficacy of anti-retroviral drugs, we
odified this system to include spreading HIV-1 infec-
ion (Limoges et al., 2000). HIV-1-infected human
DM, after 18 h of viral inoculation, were injected
tereotactically into the caudate and putamen of SCID
ice. At 1 day following the MDM inoculation, the
ercentage of HIV-1 p24 Ag expressing cells was ,1%
nd increased to a maximum of 80% at day 12 follow-
ng inoculation. Spread of infection was accompanied
y typical cytopathic effects including the formation of
ultinucleated giant cells. The increase in percentage
f HIV-1 p24 Ag-positive cells over time was linear
with a correlation coefficient of 0.975) and statistically
ignificant (P # 0.01).
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23POTENT ANTI-RETROVIRALS IN SCID MICE WITH HIVEPART affects viral replication and neuropathology
To date, knowledge regarding the penetration and
efficacy of anti-retrovirals in the CNS remains incom-
plete. Based primarily on CSF:plasma ratios, it could be
predicted that zidovudine, stavudine, and abacavir would
have the greatest CNS penetrance (all with CSF/plasma
distributions of approximately 60%). Yet, in clinical stud-
ies patients have shown neurocognitive improvement,
improvements in magnetic resonance spectroscopy
(MRS) abnormalities, and/or decrease in HIV-1 CSF RNA
while on ZDV monotherapy (Baldeweg et al., 1995; Pizzo
et al., 1988; Schmitt et al., 1988), dual therapies with
ZDV/3TC, d4T/3TC, or ZDV/ddI (Foudraine et al., 1998;
Gisslen et al., 1997; Raskino et al., 1999), or potent anti-
etroviral regimens including nucleoside or nonnucleo-
ide reverse transcriptase inhibitors (NRTIs and NNRTIs)
nd protease inhibitors (PIs) (Chang et al., 1999; Dal Pan
t al., 1998; Gendelman et al., 1998). This would suggest
hat CNS penetrance of potent anti-retroviral regimens
ay be influenced by the level of CNS pathology/inflam-
ation, which likely leads to blood–brain barrier dysfunc-
ion. Furthermore, drugs traditionally thought not to pen-
trate the CNS well may perform better in the face of
AD. To determine the effects of potent anti-retroviral
herapies on viral spread a SCID mice with HIVE was
sed. Combinations of ddI/d4T with or without amprena-
ir or a protease-sparing combination of ZDV/3TC/ABC
ere tested. These were administered at dosages and to
umbers of animals shown in Table 1. No signs of toxicity
ere seen with any of the drugs (data not shown). Rep-
icate mice were left untreated and served as controls.
ice were sacrificed at 1, 7, and 14 days postinoculation
nd brains were paraformaldehyde-fixed and paraffin-
mbedded (for determinations of cell, viral, and immune
arkers) or frozen for viral load determinations.
At 7 days following cell inoculations, equal numbers of
DM were found in basal ganglia and, to a lesser extent,
n cortex of control and drug-treated animals. Up to 80%
f human cells were HLA-DR-positive, and none of the
rug treatments affected HLA-DR expression. By day 7,
nly a small portion of the MDM were HIV-1-Ag-positive
n untreated controls and only a few human cells showed
eak immunostaining in macrophages in any of the
rug-treated animal groups. Due to low levels of viral
nfection, multinucleated giant cells were absent in both
ontrols and drug-treated mice, and no differences could
e detected between groups.
By day 14, numbers of MDM decreased in all experi-
ental groups. Importantly, drug treatment did not affect
iability of human cells (Figs. 3A–3C). Approximately 35%
f MDM in the control mouse brain expressed HIV-1 p24
g (Fig. 3D), while few to no infected cells were found in
he ddI/d4T/amprenavir-treated (Fig. 3E) or ZDV/3TC/
BC-treated mice (Fig. 3F). The dual ddI/d4T-treated
ice showed approximately 8% of MDM expressing
p
tIV-1 p24 Ag (not shown). About 8–10% of MDM in
ontrol group mice were multinucleated. This was rarely
een in the drug-treated animals.
Figure 4 summarizes the immunohistochemical data
or infected cells from four separate experiments. For
implicity, results are shown only for the highest doses of
ach drug. The average number of human MDM counted
er animal was 300 at day 1, 120 at day 7, and 85 at day
4. There was no significant change in the numbers of
ells in animal brains with or without drug treatment.
bsolute values of the percentage of HIV-1 p24 Ag ex-
ressing cells for each control group were normalized,
ith the values for the drug-treated groups expressed as
ratio to controls. This allowed comparisons between
rug treatments in separate experiments. The percent-
ge of virus-infected human cells (for all treatment
roups and controls) at day 1 after inoculation was ,1%.
t 7 days after human MDM inoculation controls were
% HIV-1 p24 Ag positive. There was no statistically
ignificant effect with or without drug treatment. How-
ver, at 14 days after inoculation the differences were
triking. Control animals showed 34% of their inoculated
DM with HIV-1 p24 Ag. In contrast, ddI/d4T-treated
nimals had 8% of cells expressing HIV-1 p24 Ag. This
as a 75% decrease compared to controls. Both triple-
rug therapy animals had ;1% of their MDM expressing
IV-1 p24 Ag (exact values were 1.2% for ddI/d4T/
mprnavir and 0.79% for ZDV/3TC/ABC). This was a 98%
ecrease compared to controls. Differences in all groups
ere highly statistically significant (P , 0.001). The
ow-dose-treated groups showed values intermediate to
hat of the controls and the high-dose groups and are not
hown.
ART affects neuroinflammation
The level of inflammatory responses to the infected
uman MDM in mouse brains was next evaluated. This
as accomplished by measures of astrogliosis, micro-
lial nodule formation, and neurofilament disruption. The
dea was to assess whether the decreased levels of
IV-1 replication could translate into alterations in neu-
opathology.
Our previous studies in this animal model have shown
hat the astrogliosis in response to needle trauma alone
s minimal and decreases after 7 days following inocu-
ation. We have also seen that inoculation of uninfected
acrophages results in approximately half the astroglio-
is demonstrated with HIV-1-infected macrophages (Per-
idsky et al., 1996). In the current experiment, at 7 days
ollowing MDM inoculations, a significant astrogliosis
as observed around the human cells in both control
nd dual-drug-treated mice. This included increases in
umber and intensity of GFAP immunostaining, with hy-
ertrophied, thick cytoplasmic processes of astrocytes in
he immediate vicinity of the injection site. Diffuse in-
-56 are
24 LIMOGES ET AL.creases in GFAP staining were seen at a distance (1000
mm) from the injected human cells. Animals treated with
either ddI/d4T/amprenavir or ZDV/3TC/ABC showed a
FIG. 1. Morphological features of HIVE in human and SCID mouse br
human (A) and mouse (B) basal ganglia. Most of these cells express
(HLA-DR-positive cells, E) and mouse tissue (F4/80-positive cells in gre
astrogliosis is detected by GFAP immunostaining in areas containing H
sections of human brain; (B, D, F, and H) serial coronal sections of SCID
to CD68 (A, B), HIV-1 p24 antigen (C, D), HLA-DR (E), and F4/80 (gree
marker) (F), GFAP (E, F). Primary antibodies (except for F4/80 and HAM
sections were counterstained with Mayer’s hematoxylin. F4/80 and HAM
(A–H).significant diminution in GFAP immunostaining in and
around the human MDM. Neither drug combination al-tered astrocyte morphology or distribution in the con-
tralateral (noninoculated) hemisphere. By day 14 a wide-
spread astrocytosis, with hypertrophy and increased
ue. Multi- and single-nucleated CD68-positive cells are present in both
p24 antigen (C, D). Activated microglia form nodules in both human
-56-positive human MDM in red, F). A pronounced and widely spread
fected cells in both human (G) and mouse (H). (A, C, E, and G) Serial
e brain (7 days after MDM inoculation) immunostained with antibodies
se macrophage/microglia antigen)/HAM-56 (red, human macrophage
detected by Vectastain Elite Kit using DAB as a substrate, and tissue
visualized by laser confocal microscopy. Original magnification, 3200ain tiss
HIV-1
en, HAM
IV-1-in
mous
n, mou
-56) areGFAP immunostaining, was found in the inoculated
hemisphere (around the needle track) of control mice
m (arrow
o w). Ori
25POTENT ANTI-RETROVIRALS IN SCID MICE WITH HIVE(Fig. 3G). The contralateral hemisphere showed a normal
distribution of astrocytes (Fig. 3J). Mice treated with ei-
ther ddI/d4T/amprenavir (Fig. 3H) or ZDV/3TC/ABC (Fig.
3I) had decreased astrogliosis in the inoculated hemi-
sphere compared to controls. Interestingly, astroglial re-
actions (GFAP immunostaining) persisted in animals
treated with ddI/d4T, at levels more prominent than that
seen in controls (data not shown). No changes were
observed in the contralateral hemispheres of any of the
animals (Figs. 3K and 3L) after 14 days of therapy. To
quantify drug effects on astrogliosis, each mouse from
each treatment group was analyzed independently.
Three to five brain sections (50 mm apart) immunola-
beled for GFAP were chosen to encompass the inocula-
tion site (one section closest to the site and one to two
rostral or caudal to it). Tissue sections were analyzed
with the Oncor V1.6 image system, and the GFAP reac-
tion was measured on both the inoculated and the con-
tralateral hemispheres and expressed as the percentage
of the brain image covered. The difference in the per-
centage of GFAP reaction between the inoculated and
the contralateral hemispheres on each section was
termed the GFAP index. This was averaged for each
mouse and each treatment group, and is shown in Fig. 5.
At 7 days following MDM inoculation, control animals
had a GFAP index of 5, which indicated 5% more area
FIG. 2. Ultrastructural features of the blood–brain barrier in SCID mou
embrane of brain microvascular endothelial cells (E). Tight junctions
f reactive astrocytes (A) contain increased amounts of glycogen (arrocovered by GFAP on the inoculated hemisphere than on
the contralateral hemisphere. Animals treated with eitherddI/d4T/amprenavir or ZDV/3TC/ABC showed a GFAP
index of ;3.7, which was a 25% decrease in astrogliosis
around the inoculation site versus controls. The dual-
therapy animals had an increased GFAP index compared
to the controls (7.8 versus 5). None of these differences
TABLE 1
Potent Anti-retroviral Treatment of HIVE SCID Mice
Treatment groups
Days following
HIV-1-infected
MDM inoculation
1 7 14
Control (untreated) 10a 12 12
ddI (12 mg/kg/day), d4T (2.4 mg/kg/day)b 4 6 6
ddI (60 mg/kg/day), d4T (12 mg/kg/day)b 4 6 6
ddI (12 mg/kg/day), d4T (2.4 mg/kg/day),
amprenavir (72 mg/kg/day)b 3 3 3
ddI (60 mg/kg/day), d4T (12 mg/kg/day),
amprenavir (360 mg/kg/day)b 6 6 6
ZDV (18 mg/kg/day), 3TC (15 mg/kg/day),
ABC (18 mg/kg/day)b 2 3 3
ZDV (90 mg/kg/day), 3TC (45 mg/kg/day),
ABC (90 mg/kg/day)b 5 6 6
a Numbers reflect total number of mice analyzed (from four indepen-
dent experiments).
b
HIVE. Human HIV-1-infected MDM (M) are located near the ablumenal
heads) between brain endothelial cells are intact. End-feet processes
ginal magnification, 34600.se withTotal daily dose of each drug given in three intraperitoneal injec-
tions.
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26 LIMOGES ET AL.reached statistical significance. At 14 days, however,
while control animals still showed a GFAP index of 5, the
triple-drug therapy groups had GFAP indices of 2.4 for
ddI/d4T/amprenavir and 3.4 for ZDV/3TC/ABC, which
was statistically significant (P , 0.001 for ddI/d4T/
amprenavir, P , 0.01 for ZDV/3TC/ABC). The dual-drug
roup, ddI/d4T, again showed an increased index of 7.8,
hich was statistically different from both controls and
he other drug-treated groups (P , 0.001). Absolute
numbers for the GFAP-covered area (7%) in this work
were lower than in our accompanying study (16%) (un-
published results). Such a discrepancy is likely related to
the methodological approach: we used the averaged
GFAP-positive area at a distance of 50–100 mm in this
study versus assessment of single coronal brain sec-
tions containing the most MDM (Limoges et al., 2000).
From previous experiments in the HIVE SCID model
we have found that the inoculation of HIV-1-infected
human MDM into the mouse brains resulted in microglial
nodule formation in and around the area of the inocu-
lated human cells. Disruption of neurofilaments and neu-
ronal apoptosis were observed in the area adjacent to
the injection site. To assess the effects of the anti-
retroviral treatments on these parameters, we identified
the brain section with the greatest numbers of MDM.
Two adjacent sections for each mouse were labeled for
either microglia (with Griffonia simplicifolia lectin
I-isolectin B4) or neurofilaments (anti-neurofilament anti-
body). Neurofilaments were principally expressed in ax-
ons and dendritic processes. For drug effects on micro-
glia, the sections were analyzed utilizing a computer-
assisted program to measure the area of the brain
section covered by microglia, which was averaged for
each treatment group. At both 7 and 14 days after MDM
inoculation drug treatment had no statistically significant
effect on microglial activation. To assess effects on neu-
rofilaments, the area of the brain section covered by
neurofilament on the inoculated hemisphere was divided
by that on the noninoculated hemisphere and was
termed the neurofilament index (with a ratio of 1 indicat-
ing a normal brain and a ratio of ,1 indicating damage
to the neuropil on the inoculated side). The neurofilament
index was averaged for each treatment group.
DISCUSSION
In this present work we show that both a protease-
sparing and a protease-containing anti-retroviral regi-
men decreased viral spread in an animal model of HIVE.
HAD is thought to be a reversible metabolic encepha-
lopathy resulting from toxic secretions from immune
stimulated virus-infected microglia and macrophages.
Numerous factors including arachidonic acid and its
metabolites, pro-inflammatory cytokines such as TNFa
or interleukin-1 b, quinolinic acid, and viral proteins
(gp120, gp41, Tat), among others, have been implicated in
a
wthe neuropathology (Bukrinsky et al., 1995; Gelbard et al.,
1994; Genis et al., 1992; Griffin et al., 1994; Heyes et al.,
991; Lipton et al., 1993; Nottet et al., 1995; Tyor et al.,
992; Wesselingh et al., 1993). Most recently, studies
rom our laboratory and those of others indicated that
rogeny virions may bind to chemokine receptors (for
xample, CXCR4) expressed on neurons and alter intra-
ellular signaling, perhaps leading to apoptosis (Hessel-
esser et al., 1998; Zheng et al., 1999). Clearly, the mech-
nism of HIV-1-associated brain injury is complex, prob-
bly involving more than one of these neurotoxic factors
orking in synergy with a number of cellular and/or viral
actors (Shi et al., 1996). From our previous experiments
n this animal model (Persidsky et al., 1996), we know
hat the mouse brains develop neuropathology and in-
lammatory reactions that parallel human HIVE. These
tudies provide additional evidence supporting the im-
ortance of HIVE SCID mice for evaluation of potential
herapeutic regimens that could be applied to humans.
nti-retroviral responses paralleled, in measure, the pre-
ention of a multinucleated giant cell encephalitis, an
mportant pathological indication of HIVE.
Since the advent of potent anti-retroviral therapy for
IV-1, usually consisting of at least three drugs combin-
ng 1 or 2 NRTIs with either 1 or 2 PIs or an NNRTI, the
ncidence of both opportunistic diseases (Brodt et al.,
997) and HAD has markedly decreased (Brodt et al.,
997; Sacktor et al., 1999). A number of studies have
hown improvements in neuropsychologic performance
Ferrando et al., 1998; Price et al., 1999; Tepper et al.,
998), in brain metabolite abnormalities (Chang et al.,
999), and in CSF markers of inflammation (Gendelman
t al., 1998) in patients receiving various potent anti-
etroviral regimens. Treatment with potent regimens has
lso been associated with a lower risk for progression to
AD (Childs et al., 1999). As promising as these statistics
ay be, a study done in Australia by Dore et al. (1999)
howed lesser declines in the rate of HAD compared to
hat of opportunistic infections, which resulted in a pro-
ortional increase in HAD as an AIDS defining illness. As
atients live longer with HIV, the potential exists that
AD may become a more frequent complication of viral
nfection. Thus, the development of potent anti-retroviral
egimens to specifically target the CNS or prevent HAD
ill become more imperative, as will the evaluation of
he relative superiority (or lack thereof) of particular drug
ombinations.
Even in the absence of HAD, targeting the CNS is
mportant for long-term efficacy of potent anti-retroviral
herapy due to the potential for the CNS to act as a viral
eservoir. HIV-1 can persist for long periods of time (and
ence evade anti-retroviral therapy) in latently infected
ells, which include resting CD41 T-cells and macro-
hages. The virally infected cells in the CNS are gener-
lly perivascular macrophages and resident microglia,
here HIV-1 can persist in a “near” latent stage. Addi-
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27POTENT ANTI-RETROVIRALS IN SCID MICE WITH HIVEtionally, many of the drugs used in potent anti-retroviral
regimens, especially the protease inhibitors, may have
variable or marginal CNS penetrance, which could lead
to development of resistance. A number of studies sup-
port the importance of the CNS as a relatively “separate”
virus population. For instance, high-level ZDV resistance
has been found in the CNS virus population in the ab-
sence of similar resistance in peripheral blood. In addi-
tion, other studies show differing viral kinetics in re-
sponse to anti-retroviral therapy in the CNS and plasma
(Ellis et al., 2000; Staprans et al., 1999), suggesting that
the CNS and periphery may represent distinct viral pop-
ulations. Targeting the CNS and other tissue viral reser-
voirs will likely play a pivotal role in the success of any
new PART therapies.
One important finding shown here was the ability to
decrease inflammation in the animal brains (decreased
astrogliosis) by treating viral infection. It is accepted that
indirect mechanisms play a major role in neuronal dys-
function and death caused by host secretory products or
viral toxic components during HIVE/HAD. Virus-infected
microglia and macrophages upon immune stimulation
secrete a number of factors that cause neurotoxicity. In
this study, we showed that viral infection and astrogliosis
were decreased in parallel. However, lower levels of viral
suppression (in the dual-drug-treated animals) actually
increased astrocytic responses. Since the dual-drug-
therapy arm contained the drugs ddI and d4T, both of
which are known to have significant incidences of pe-
ripheral neuropathy (Moore et al., 2000), it is possible
that the combination had distinct CNS toxicity, which
accounted for the increased GFAP staining. Additionally,
in a separate study in the same SCID mouse model of
HIVE, we used two anti-inflammatory drugs, a TNFa
release inhibitor and a PAF inhibitor, which in combina-
tion were successful in decreasing some of the inflam-
matory neuropathology without affecting the level of viral
infection (Persidsky et al., unpublished results). These
esults, combined with the fact that the levels of immune
ctivated MP have been shown to be a better correlate
ith HIV-1 dementia than absolute levels of virus (Glass
t al., 1995), would suggest that optimal treatment may
equire a multipronged approach targeting both the virus
nd subsequent inflammatory reactions.
Some caveats of our findings in this animal model
hould be noted. The most notable is that therapeutic
esults in an animal model of a uniquely human disease
annot be directly translated. Our results should not
ndicate that ZDV/3TC/ABC or ddI/d4T/amprenavir is su-
erior to other potent anti-retroviral regimens for HAD,
ut should raise the issue that any anti-retroviral regimen
hat achieves high levels of viral suppression may be
fficacious for CNS disease. It should also be noted that
TC alone in our previous study was capable of decreas-ng the level of infected MDM by 98% versus controls,
imilar to what was seen here with either of the triple-
e
vdrug regimens, although the actual percentages of HIV-1
p24 Ag-positive cells was lower in the ZDV/3TC/ABC
group than that seen in the 3TC group in the single-drug
studies. Also, in these single-drug treatment studies we
did not see any decrease in the levels of astrocytosis, as
we did with the triple-drug groups, suggesting that the
anti-retroviral effects of these combinations cannot be
measured solely by effects on HIV-1 p24 antigen expres-
sion. Additionally, the treatments are given at the time of
cell inoculations (an unlikely event in human disease),
and relatively large numbers of cells are introduced in
the animal brains at one time with a subsequent rapid
spread of infection. This is in contrast to disease in
humans, which develops over years and may involve few
infected cells initially. However, the SCID mouse HIVE
model does allow relatively rapid screening of different
anti-retroviral regimens, as well as anti-inflammatory and
other neuroprotective agents. Although the histopatho-
logic analyses are somewhat complex and labor-inten-
sive, the model is still cheaper and easier to handle than
larger animal models. Our laboratory is currently in the
process of establishing behavioral testing and evalua-
tion of neuronal functions by electrophysiological meth-
ods and correlating behavioral and neuronal abnormali-
ties with neuropathology. Additionally, we will use MRS
to assay metabolic changes in the brains of SCID mice
with HIVE versus controls (unmanipulated or sham-inoc-
ulated SCID mice) and again correlate this with neuro-
pathology. If one or both of these modalities are found to
correlate with the pathologic changes, they may prove to
be additional, if not easier, methods of assaying treat-
ment paradigms. Furthermore, these cross-validating
analyses will be very important in potential side effects of
current potent anti-retroviral regimens used for pro-
longed periods of time.
One critical element in considering choices of anti-
retroviral regimens centers around ways to enhance
CNS penetrance by the drug. Indeed, many of the current
anti-retrovirals in clinical practice have limited perme-
ability across the blood–brain barrier. Membrane-bound
drug efflux proteins, such as P-glycoprotein (P-gp), are
one component of the blood–brain barrier that can limit
drug delivery into the CNS (Fontaine et al., 1996; Huai-
Yun et al., 1998; Starling et al., 1997; Wang et al., 1995;
ang et al., 1996). Pluronic block copolymers (nonionic
lock copolymeric surfactants) are potent inhibitors of
rug efflux systems in brain microvascular endothelial
ells (BMVECs, a critical component of the blood–brain
arrier) (Batrakova et al., 1998a, 1998b, 1999a, 1999b;
iller et al., 1997) and have been shown in vitro to
ncrease permeability of bovine BMVECs to a number of
rugs including protease inhibitors and ZDV (Batrakova
t al., 1999a,b). Clinical toxicity of such drugs has
locked their widespread use (Alakhov et al., 1999). How-
ver, new cogeners of block copolymers are being de-
eloped to make this a more attractive option for future
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30 LIMOGES ET AL.clinical interventions (A. Kabanov, personal communica-
tion). In addition, though structurally intact, the blood–
brain barrier could be functionally compromised (as in
HIV-1-infected human brain), as found in our recent work
where we demonstrated focal down-regulation of P-gp
on BMVECs both in the SCID mouse model and in
human brain tissue with HIV-1 encephalitis (Persidsky et
al., 2000).
In summary, the development of potent anti-retroviral
regimens that abrogate HIV-1 replication in the CNS
remains of critical importance toward possible eradica-
tion of virus in hidden sanctuaries. Indeed, HIV-1 can
persist in brain even following potent regimens such as
those studied in this report. This occurs because of
failure of the drug to penetrate the blood–brain barrier,
back-seeding of virus from brain to blood, or specific
inflammatory responses in brain that instigate continu-
ous viral replication. The use of such a murine model
system for HIVE is critical for the development of new
anti-retrovirals with increased CNS efficacy if eradication
of HIV-1 is to be achieved in brain. This work begins to
address such issues. Such an animal system can inev-
itably be used to monitor the biologic, immune, and
physiologic effects of HIV-1 replication in brain MP.
These works should ultimately yield unique insights into
how the brain’s immune system is affected by viral rep-
lication and how neurodegeneration is caused and how
it can be prevented.
MATERIALS AND METHODS
Isolation and culture of primary human monocytes
Monocytes were obtained from leukaphoresis of HIV-1,
FIG. 4. Effects of potent anti-retroviral therapies on viral replication in
HIVE SCID mice. Histologic data from all mice, from all experiments,
were analyzed, and the percentage of MDM expressing HIV-1 p24 Ag
(out of the total cells detected) was averaged for each treatment group
at each time point. All controls were averaged and the values for the
drug treatment groups were normalized to the average control value, to
allow comparison between separate experiments. Results are shown
for all high-dose groups. The average number of detected MDM was
similar in each treatment group. Bar values represent means 6 SEM
from six animals. Statistical analysis performed by one-way ANOVA
with Newman–Keuls posttest.HIV-2, and hepatitis B seronegative donors and purified
by countercurrent centrifugal elutriation (Gendelman etal., 1988). Cell suspensions were documented as .98%
monocytes by criteria of cell morphology in Wright-
stained cytosmears and CD68 immunostaining. Mono-
cytes were cultured as suspensions in Teflon flasks (2 3
106 cells/ml) in DMEM (Sigma Chemical Co., St. Louis,
MO) with 10% heat-inactivated pooled human serum, 1%
glutamine, 50 mg/ml gentamicin (Sigma), 10 mg/ml cipro-
loxacin (Sigma), and 1000 U/ml highly purified recombi-
ant human macrophage colony-stimulating factor
MCSF) (a generous gift from Genetics Institute, Inc.,
ambridge, MA). MCSF was placed into culture for the
nitial 7 days of monocyte cultivation (to promote cell
ifferentiation) and then removed. Culture medium was
hanged every 3 days. All tissue culture reagents were
creened before use and found negative for endotoxin
,10 pg/ml; Associates of Cape Cod., Inc., Woods Hole,
A) and mycoplasma (Gen-probe II; Gen-probe Inc., San
iego, CA).
IV-1 infection of MDM
After 7 days in Teflon flask suspension culture, MDM
ere infected with HIV-1ADA (a macrophage tropic strain)
at multiplicity of infection of 0.01 infectious virus/target
cell (Gendelman et al., 1988). Reverse transcriptase ac-
tivity was determined in triplicate samples of culture
fluids added to a reaction mixture of 0.05% Nonidet-P40
(Sigma), 10 mg/ml poly(A), 0.25 mg/ml oligo(dT) (Pharma-
cia Fine Chemicals, Piscataway, NJ), 5 mM dithiothreitol
(Pharmacia), 150 mM KCl, 15 mM MgCl2, and [
3H]dideoxy
thymidine 59-triphosphate (2 Ci/mmol; Amersham Corp.,
Arlington Heights, IL) in pH 7.9 Tris–HCl buffer for 18 h at
37°C. Radiolabeled nucleotides were precipitated with
cold 10% trichloroacetic acid and 95% ethanol in an
automatic cell harvester (Skatron Inc., Sterling, VA) on
paper filters. Radioactivity was estimated by liquid scin-
tillation spectroscopy (Kalter et al., 1991). The percentage
of HIV-infected MDM was determined by immunolabel-
FIG. 5. Effect of potent anti-retroviral therapies on astrogliosis in
HIVE SCID mice. Levels of GFAP expression were analyzed in the
inoculated versus the contralateral hemispheres utilizing a computer-
assisted imaging system, with three to five sections assayed per
animal. The difference between the inoculated and the contralateral
hemispheres was expressed as the GFAP index and averaged for each
animal and each time point. Bar values represent means 6 SEM from
6 animals (12 for controls). Statistical analysis was performed by one-
way ANOVA with Newman–Keuls posttest.
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31POTENT ANTI-RETROVIRALS IN SCID MICE WITH HIVEing with anti-HIV-1 p24 monoclonal antibody (mAb; Dako
Corp., Carpinteria, CA). Cytospin preparations of HIV-1-
infected cells were fixed in cold absolute acetone:metha-
nol (1:1) for 10 min at 220°C. Anti-HIV-1 p24 mAb (1:10;
ako) was applied for 60 min at room temperature,
ollowed by treatment with a FITC-conjugated anti-
ouse IgG, F(ab9)2 fragment (1:100; Boehringer Mann-
heim Corp., Indianapolis, IN) for 1 h at room temperature.
Viral antigen-positive cells were counted with a FITC
filter in a Nikon Microphot-FXA microscope (Nikon, To-
kyo, Japan) using a 203 objective in 10 random fields. All
experiments were performed in triplicate.
SCID mouse model of HIVE
The SCID mice (male C.B-17/IcrCrl-scidBR, 3–4 weeks
old) were purchased from Charles River Laboratories
(Wilmington, MA). Animals were maintained in sterile
microisolator cages under pathogen-free conditions in
the Laboratory of Animal Medicine at the University of
Nebraska Medical Center in accordance with ethical
guidelines for care of laboratory animals set forth by the
National Institutes of Health. All animal manipulations
(including intracerebral inoculations) were made in a
laminar flow hood. Intracerebral inoculations of HIV-1ADA-
nfected MDM were performed following intraperitoneal
ip) ketamine/xylazine anesthesia (100 mg/kg ketamine
nd 16 mg/kg xylazine). On the day of brain inoculation (1
ay postinfection) cells were pelleted. A MDM suspen-
ion of 2 3 107 cells/ml (in serum-free DMEM) was
repared for inoculations. Anesthetized mice were
laced in a stereotaxic apparatus (Stoetling Co., Wood
ale, IL) designed specifically for mice. The animal’s
ead was secured with earbars and mouthpiece as pre-
iously described (Cunningham and McKay, 1993). A 1-ml
uberculin syringe (Becton Dickinson, Franklin Lakes, NJ)
ith a 26-gauge needle was utilized for cell inoculations.
ach animal brain received 15 ml of suspension contain-
ing 3.0 3 105 HIV-infected cells, inoculated into the left
emisphere targeting caudate and putamen, with coor-
inates as previously described (Persidsky et al., 1996).
nimals were sacrificed at 1, 4, 7, or 14 days postinocu-
ation for initial spreading infection studies or at 1, 7, and
4 days for drug treatment studies. Similar numbers of
uman MDM were identified in the brains of animals, in
ach treatment group, by morphological and immunohis-
ochemical analyses.
istopathology and image analysis
Brain tissue was collected at necropsy. Tissue was
ixed in 4% phosphate-buffered paraformaldehyde and
araffin-embedded (for immunohistochemistry) or snap-
rozen in liquid nitrogen (for immunofluorescence). Im-
unohistochemistry was performed on 5-mm paraform-aldehyde-fixed, paraffin-embedded sections. Human
MDM were identified immunocytochemically with anti-CD68 KP-1 (1:100; Dako) or anti-vimentin (1:25; Boeh-
ringer Mannheim) mAbs. Mouse astrocytes were recog-
nized with polyclonal Abs against GFAP (from Dako and
used at 1:1000 dilution). Human HLA-DR (Boehringer
Mannheim) at a 1:25 dilution and HIV-1 p24 antigen
(Dako) at a 1:10 dilution (mAbs) were used to detect
cellular and viral gene products, respectively. Mouse
microglia were identified with biotinylated G. simplicifolia
lectin I-isolectin B4, for paraffin sections (Vector Labora-
tories, Burlingame, CA) or rat F4/80 mAb (1:5 dilution;
Serotech, Kidlington, NY) for frozen sections. Mouse neu-
rons were labeled with mAbs for the phosphorylated
form of neurofilament (Dako, used at a dilution of 1:100).
To detect antigens (CD68, HLA-DR, HIV-1 p24, GFAP,
neurofilament, vimentin) on paraffin sections avidin–bi-
otin immunoperoxidase staining with a Vectastain Elite
ABC kit (Vector Laboratories) was used with 3,39-diami-
nobenzidine as the chromogen. All sections were coun-
terstained with Mayer’s hematoxylin. Deletion of the pri-
mary antibody or use of mouse IgG or rabbit IgG (Dako)
served as controls. Immunostained tissues were ana-
lyzed with a Nikon Microphot-FXA microscope. Indirect
immunofluorescence detection (secondary antibodies)
was performed for HAM-56 and F4/80 (double-labeling)
using rhodamine-coupled anti-mouse IgM, F(ab9)2 frag-
ment (Boehringer Mannheim; at a 1:50 dilution) and FITC-
coupled goat anti-rat Ab, F(ab9)2 fragment (1:25 dilution;
Biosource, Camarillo, CA). Immunolabeled frozen sec-
tions were examined in a laser confocal microscope
(Zeiss LSM 410, Germany), and digital images were ac-
quired as described previously (Persidsky et al., 1997).
For histologic analyses, 60 initial sections (20 sections
each from 3 blocks) were cut from each mouse brain,
and every fifth section was immunostained for GFAP or
CD68 to identify the site of inoculation. If no human cells
were identified, 30 more sections were cut from blocks
until the inoculation site was identified or all the tissue
was sectioned. For each brain section containing more
than five MDM, a paired (adjacent) section was labeled
with antibody to HIV-1 p24 Ag (as previously described),
to generate the percentage of HIV-1-infected MDM. Re-
sults were averaged for each mouse and treatment
group. For measurement of drug effect on GFAP expres-
sion, 3 to 5 sections encompassing the inoculation site
(spanning 100–200 mm) were analyzed using the com-
puter-assisted system, Oncor Image V1.6 (Oncor, Gaith-
ersburg, MD), with a cooled CCD camera (Photometrics,
Tucson, AZ). One field per slide (corresponding to a 103
objective) was scanned in the putamen and cortex of
inoculated and contralateral brain hemispheres of each
animal. The scanned zone covered 1000 mm medially
and laterally from the needle tract on the coronal section
and allowed measurement of the entire “astrogliosis re-
action” on the section. GFAP immunolabeled areas were
expressed as a percentage of the brain image. The
difference in the percentage of GFAP reaction between
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32 LIMOGES ET AL.the inoculated and the contralateral hemispheres on
each section was averaged for each mouse and each
treatment group. For effects on neurofilament and micro-
glial reaction, 1 or 2 sections closest to the inoculation
site were analyzed. Ten to 15 fields were scanned per
section (corresponding to a 203 objective) around the
noculation site and the contralateral hemisphere, to al-
ow measurement of the entire area. The neurofilament
mmunostained areas were expressed as a percentage
f the brain image. The ratio of the neurofilament reac-
ion of the inoculated hemisphere, versus the contralat-
ral hemisphere was averaged for each mouse and each
reatment group. For the microglial reaction, the lectin-
abeled area was expressed as a percentage of the brain
mage and averaged for each mouse and each treatment
roup.
rug treatment
Just prior to intracerebral inoculation of HIV-1-infected
DM, animals were given drugs by ip injection, with the
otal daily dose split into a three-time daily regimen, at
mounts shown in Table 1. The doses of all drugs were
etermined to be representative of what is administered
o humans and by previous studies in the animal model
Limoges et al., 2000). In the case of amprenavir, drug
dministration was used as suggested by the manufac-
urer (GlaxoWellcome) based upon preclinical studies in
odents. Drug administration was continued at the same
osing regimen daily until the time of animal sacrifice.
tatistical analyses
Data were analyzed using Graphpad Prism 2.0 soft-
are (Macintosh, 1994) with one-way ANOVA with New-
an–Keuls posttest (for multiple comparisons).
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